Innovating Works
SC1-BHC-05-2018
SC1-BHC-05-2018: International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches
Specific Challenge:The EU has ample experience in building and running data repositories to support biomedical research. Notable initiatives are ELIXIR[1] and the European Genome-phenome Archive[2], storing many types of data up to the population-wide level. Similar expertise exists in Canada notably via IHEC (International Human Epigenome Consortium[3]) and its Data Portal[4] as well as PhenomeCentral, a repository for clinicians and scientists working on human rare disorders[5].
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 18-04-2018.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:The EU has ample experience in building and running data repositories to support biomedical research. Notable initiatives are ELIXIR[1] and the European Genome-phenome Archive[2], storing many types of data up to the population-wide level. Similar expertise exists in Canada notably via IHEC (International Human Epigenome Consortium[3]) and its Data Portal[4] as well as PhenomeCentral, a repository for clinicians and scientists working on human rare disorders[5].

There is a recognised need for tools that allow researchers to manage, exchange and preserve their data efficiently. Data repositories are scattered around the world and often do not use compatible data standards. There is a pressing need for better integration of public repositories, coordinated data sharing and sustainable storage of high value data. Apart from hardware and maintenance costs, the cost of data curation, a necessary element to foster progress in biology and medicine, also needs to be considered.


Scope:To build a collaboration of stakeholders in Europe and Canada in the domain of repositories storing and sharing human –omics data that will create a framewor... ver más

Specific Challenge:The EU has ample experience in building and running data repositories to support biomedical research. Notable initiatives are ELIXIR[1] and the European Genome-phenome Archive[2], storing many types of data up to the population-wide level. Similar expertise exists in Canada notably via IHEC (International Human Epigenome Consortium[3]) and its Data Portal[4] as well as PhenomeCentral, a repository for clinicians and scientists working on human rare disorders[5].

There is a recognised need for tools that allow researchers to manage, exchange and preserve their data efficiently. Data repositories are scattered around the world and often do not use compatible data standards. There is a pressing need for better integration of public repositories, coordinated data sharing and sustainable storage of high value data. Apart from hardware and maintenance costs, the cost of data curation, a necessary element to foster progress in biology and medicine, also needs to be considered.


Scope:To build a collaboration of stakeholders in Europe and Canada in the domain of repositories storing and sharing human –omics data that will create a framework for long-term cooperation. In order to do so, this programme aims to enhance and standardise data deposition, curation and exchange procedures thus ensuring better data reuse and increased benefit to the scientific communities worldwide. The selected projects should build on the data quality metrics, standards and access policies developed by major international initiatives (e.g., IHEC, ICGC[6], IHMC[7], MME[8]).

Considering the existing data policies, projects should develop approaches that integrate data from disparate sources and include one or more of the following elements:

Data models that guarantee the interoperability of human health research data from different repositories and integrate different types of –omics data and, where relevant, clinical research and lifestyle data. The data models should take into account sex/gender differences where relevant. The projects should build on existing research infrastructures such as –omics repositories, biobanks and registries.Reference architecture for data and process interoperability.Technologies and methodologies for data harvesting, data access, data transfers, and archiving complex datasets.Bioinformatics toolbox to support the analysis and management of data on diseases from a personalised medicine standpoint.International ethical and legal governance model for a research data management and storage infrastructure and an associated data management plan compliant with the required level of data security and privacy that is aligned with the recent recommendations of the OECD Council on Health Data Governance[9]. This topic raises important issues of data sharing, privacy protection, informational right to self-determination and data security, which should be addressed from a legal, ethical as well as a social sciences perspective. It is important that proposals enable sustainable, collaborative projects and ensure cross-references with existing infrastructures (e.g., BBMRI-ERIC, ELIXIR) and other on-going initiatives (e.g., International Consortium for Personalised Medicine[10], European Open Science Cloud[11], IHEC, etc.). Synergies should be sought with other projects (e.g. calls under the Innovative Medicines Initiative (IMI)[12] and running IMI projects[13]). The proposals should take stock of the BBMRI-ERIC Code of Conduct for using personal data in health research. A multidisciplinary approach, i.e., involving clinicians, biologists, bioinformaticians, etc., is considered a key aspect of successful proposals. Due to the specific challenge of this topic, in addition to the minimum number of participants set out in the General Annexes, proposals shall include at least one participant from Canada.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting different amounts. In addition to the EU/Associated Countries and Canada, the proposed project consortia may include other international partners. SME participation is encouraged.


Expected Impact: Intensified sharing, reuse, collaboration and knowledge discovery in the health field, while ensuring legal safety on the use of the data. Integration of various health and disease data in data-intensive fields such as personalised medicine. More efficient research through reduced duplication of experimentation. A network of research infrastructures and databases in the EU and Canada that build synergies between ongoing activities, contributing to delivering the backbone for new discoveries that address the Societal Challenges delineated in Horizon 2020[14]. Strengthened position of the EU and Canada in science and more collaboration between academia and industry resulting in more innovation, jobs and growth. Contribute to the Digital Single Market through piloting IT health research solutions. Further the “Open science” and “Open to the world” priorities and contribute to the Health Research and Innovation Cloud, one of the thematic clouds of the European Open Science Cloud.
Cross-cutting Priorities:Open ScienceSocio-economic science and humanitiesGenderInternational cooperation


[1]the pan-European infrastructure for life sciences data https://www.elixir-europe.org/

[2]https://ega-archive.org/

[3]http://ihec-epigenomes.org/ and http://ihec-epigenomes.org/about/policies-and-guidelines/

[4]maintained at the Montreal Neurological Institute http://epigenomesportal.ca/ihec/

[5]http://www.phenomecentral.org

[6]https://dcc.icgc.org/

[7]http://www.human-microbiome.org/

[8]http://www.matchmakerexchange.org

[9]https://www.oecd.org/health/health-systems/Recommendation-of-OECD-Council-on-Health-Data-Governance-Booklet.pdf

[10]http://www.icpermed.eu/

[11]https://ec.europa.eu/research/openscience/pdf/realising_the_european_open_science_cloud_2016.pdf

[12]https://www.imi.europa.eu/content/imi-2

[13]ETRIKS: https://www.etriks.org/, EMIF: http://www.emif.eu/, OPEN-PHACTS: https://www.openphacts.org/

[14]https://ec.europa.eu/programmes/horizon2020/en/h2020-section/societal-challenges

ver menos

Temáticas Obligatorias del proyecto: Temática principal: Personalised medicine Interoperability Health services health care research

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Specific Challenge:The EU has ample experience in building and running data repositories to support biomedical research. Notable initiatives are ELIXIR[1] and the European Genome-phenome Archive[2], storing many types of data up to the population-wide level. Similar expertise exists in Canada notably via IHEC (International Human Epigenome Consortium[3]) and its Data Portal[4] as well as PhenomeCentral, a repository for clinicians and scientists working on human rare disorders[5]. Specific Challenge:The EU has ample experience in building and running data repositories to support biomedical research. Notable initiatives are ELIXIR[1] and the European Genome-phenome Archive[2], storing many types of data up to the population-wide level. Similar expertise exists in Canada notably via IHEC (International Human Epigenome Consortium[3]) and its Data Portal[4] as well as PhenomeCentral, a repository for clinicians and scientists working on human rare disorders[5].
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
1. Eligible countries: described in Annex A of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme. 
Due to the specific challenge of this topic, in addition to the minimum number of participants set out in the General Annexes, proposals shall include at least one participant from Canada.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion in a single stage process will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
Specific provis...
1. Eligible countries: described in Annex A of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme. 
Due to the specific challenge of this topic, in addition to the minimum number of participants set out in the General Annexes, proposals shall include at least one participant from Canada.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion in a single stage process will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
Essential information for clinical studies
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.
8. Additional documents:
Introduction WP 2018-20
Health, demographic change and well-being WP 2018-20
General annexes to the Work Programme 2018-2020
Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-SC1-BHC-2018-2020 International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches Specific Challenge:The EU has ample experience in building and running data repositories to support biomedical research. Notable initiatives...
Sin info.
SC1-BHC-17-2020 Global Alliance for Chronic Diseases (GACD) - Prevention and/or early diagnosis of cancer
en consorcio: Specific Challenge:The Global Alliance for Chronic Diseases[1] (GACD) call will focus on implementation research proposals for the preventio...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-BHC-34-2020 New approaches for clinical management and prevention of resistant bacterial infections in high prevalence settings
en consorcio: Specific Challenge:Antimicrobial resistance represents a serious threat to public health in Europe and beyond. Within the last decades resis...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-BHC-36-2020 Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health
en consorcio: Specific Challenge:Global plastic production has increased exponentially over the past decades. A significant proportion of the plastic prod...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-BHC-20A-2020 Pre-commercial procurement (PCP) for integrated care solutions
en consorcio: Specific Challenge:The challenge is to enable public procurers to collectively implement PCPs in order to close the gap between supply and d...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-BHC-35-2020 Creation of a European wide sustainable network for harmonised large-scale clinical research studies for infectious diseases
en consorcio: Specific Challenge:Infectious diseases pose a serious threat to human health and there are many challenges and needs to efficiently protect...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de